FDA clears Talzenna with enzalutamide for earlier HRR-mutated prostate cancer

The Food and Drug Administration has moved an established prostate-cancer drug combination to an earlier stage of the disease. On 26 October 2026 the agency approved talazoparib, sold by Pfizer as Talzenna, together with enzalutamide, for adults with metastatic prostate cancer that is "androgen pathway modulation-naïve or -sensitive" and carries mutations in homologous recombination repair (HRR) genes, detected by an FDA-authorised test [s1]. The supplement was recorded in the agency's Drugs@FDA database the same week [s2].

The jargon marks the shift. Talazoparib with enzalutamide was first cleared in 2023 for HRR-mutated metastatic castration-resistant disease — cancer that has learned to grow despite treatment that shuts down testosterone. The new approval reaches patients before that point, when the cancer still responds to hormonal therapy. Catching the disease while it is still hormone-sensitive is where oncologists most want effective combinations, because that is when there is the most to protect.

What talazoparib does

Talazoparib is a PARP inhibitor. PARP is an enzyme that helps cells patch breaks in their DNA. Blocking it is most damaging to cancer cells that already have a second weakness in DNA repair — exactly the HRR gene mutations this approval requires. With both repair routes disabled, the damage accumulates and the cell dies. That is why the drug is paired with a genetic test rather than offered broadly: the benefit is concentrated in tumours carrying those mutations [s1].

Enzalutamide is a different kind of drug, an androgen-receptor blocker that starves prostate cancer of the hormonal signal it feeds on. The rationale for combining the two is that each attacks the cancer through a separate mechanism, and patients also stay on continuous androgen deprivation therapy underneath [s1].

What the trial showed

The approval rests on TALAPRO-3, a randomised, double-blind, placebo-controlled trial that tested talazoparib plus enzalutamide against placebo plus enzalutamide in this HRR-mutated, hormone-sensitive population [s3]. The main measure was radiographic progression-free survival — how long patients lived before scans showed the cancer advancing, or they died.

The difference was large. In the talazoparib arm the median was not reached, meaning more than half of patients had still not progressed when the data were analysed; in the placebo arm it was 45.8 months [s1]. The hazard ratio was 0.48, with a 95% confidence interval of 0.36 to 0.65 and a p-value below 0.0001 — a roughly halved risk of radiographic progression or death, with a confidence interval comfortably clear of no effect [s1].

Overall survival — whether people actually live longer — was not yet answerable. At the time of this analysis, the FDA noted, the survival data were immature, meaning too few deaths had occurred to judge [s1]. That is the honest limit of the result: a strong delay in progression on imaging, with the question of longevity still open.

The cautions

The recommended dose is talazoparib 0.5 mg orally once daily with enzalutamide, continued until the disease progresses or side effects become unacceptable [s1]. The drug's labelling carries serious warnings. PARP inhibitors can suppress the bone marrow, lowering blood counts, and in rare cases have been linked to myelodysplastic syndrome and acute myeloid leukaemia — cancers of the blood themselves [s1]. The combination can also harm a developing fetus, though that caution matters less in this older male population [s1].

For prostate-cancer patients and their doctors, the practical message is narrower than the headline. This is not a treatment for everyone with advanced prostate cancer. It applies to those whose tumour testing shows an HRR mutation, and the demonstrated benefit so far is a delay in progression on scans rather than proven longer life [s1]. The genetic test is not optional; it is the gate that decides who the combination is likely to help [s1].

What the approval does establish is a pattern now common across oncology: a drug proven in late, treatment-resistant disease, paired with a biomarker test, and then moved earlier once a trial shows it still works when the cancer is more treatable. Whether that earlier use translates into longer lives is the question TALAPRO-3's maturing survival data will eventually answer [s1][s3].

Red flags: anyone taking a PARP inhibitor who develops unusual bruising, bleeding, persistent fatigue, breathlessness, fever or recurrent infections should contact their care team, as these can signal falling blood counts. This article describes a regulatory decision and clinical-trial findings and is not medical advice. Decisions about prostate-cancer treatment, including genetic testing, are for patients and their treating oncologists.